Skip to main content

Table 6 Comparison between the patients with HCC and those without HCC in the 137 patients without past history of IFN treatment

From: PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients

 

Patients with HCC

Patients without HCC

Comparison between patients with HCC and those without HCC

Multiple regression analysis for factors associated with HCC development

(n = 31)

(n = 106)

Odds ratio (95% confidence interval)

p

Age (yrs)

70.9±7.1

62.3±11.9

P = 0.0002

1.09 (1.04 - 1.15)

p = 0.0006

Gender (male/female)

16/15

48/58

NS

 

NS

BMI (kg/m2)

23.1±4.0

21.9±3.4

NS

  

PNPLA3 (GG/CC・CG)

8/23

14/92

P = 0.0928

 

NS

AST (IU/L)

80.7±64.3

51.4±41.8

P = 0.0032

  

ALT (IU/L)

65.5±50.0

63.9±84.1

NS

  

γ-GTP (IU/L)

53.5±40.7

60.0±73.6

NS

  

Albumin (g/dL)

3.4±0.56

4.2±0.5

p < 0.0001

  

Total bilirubin (mg/dL)

1.5±1.1

0.8±0.4

p < 0.0001

  

Platelet count (x104/μL)

9.2±4.3

14.1±5.5

P = 0.0008

  

Prothrombin time (%)

81.5±14.0

96.0±19.7

P= 0.0002

  

Hyaluronic acid (ng/mL)

507.0±542.5

202.1±313.7

P = 0.0002

  

α-fetoprotein (ng/mL)

475.9±1411.2

28.7±148.1

P = 0.0016

  

PIVKA-II(mAU/mL)

47.0±51.0

20.8±10.7

p < 0.0001

  

HCV genotype (1/2/3)

27/4/0

82/23/1

NS

  

HCV RNA (log IU/mL)

5.9±1.0

6.2±0.9

NS

  

Velocity of shear wave (m/s)

2.20±0.70

1.55±0.50

p < 0.0001

  
  1. HCC, hepatocellular carcinoma; IFN, interferon; BMI, body mass index; NVR, non-virological response; PNPLA3, patatin-like phospholipase domain-containing 3; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein induced by Vitamin K absence or antagonist-II; NS, not significant.